secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0000886163-25-000058
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q3 revenue $115.5M, net income $117.3M; raises FY guidance
-----------------------------------------------------------------

- Q3 royalties $46.6M, up 47% YoY, driven by Filspari, Ohtuvayre, Qarziba.
- Adjusted EPS $3.09 vs $1.84 YoY; GAAP net income $117.3M ($5.68 diluted).
- FY 2025 core revenue guidance raised to $225M-$235M; core adj. EPS $7.40-$7.65.
- Closed $460M 0.75% convertible notes due 2030; net proceeds ~$445M.
- New royalty investments: $7M for AT220/AT292 rights; $25M in Orchestra BioMed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000058/0000886163-25-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000058/lgnd-20251106.htm
  HTML page:      https://secwatch.observer/filing/0000886163-25-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer